Fig. 4
Tucidinostat improves the efficacy of checkpoint blockade and induces a durable response. a Schema of the experiment. Mouse 4T1, LLC, and CT26 cells (5 × 105 cells) were engrafted into the flank of BALB/c or C57 BL/6 mice. When established tumors were palpable 7 days after tumor cell inoculation, mice were treated with vehicle (DMSO, n=7), tucidinostat (25 mg/kg, gavage, daily, n=7), aPD-L1 (200 μg, i.p. injection, once every 3 days, n=7), or combination (n=7). Tumor volume was measured with calipers every 3 days. b Tumor growth curves (left) of these mice at day 33 post-treatment initiation are shown in the 4T1 mouse tumor model. Tumor weight (middle) and mouse weight of these mice (right) at day 21 post-treatment initiation are shown. c Tumor growth curves (left), tumor weight (middle), and mouse weight (right) of these mice at day 21 post-treatment initiation are shown in the LLC mouse tumor model. d Tumor growth curves (left), tumor weight (middle), and mouse weight (right) of these mice at day 21 post-treatment initiation are shown in the CT26 mouse tumor model. e Kaplan-Meier survival curves of these mice are shown in 4T1, LLC, and CT26 mouse tumor models. The error bars indicate mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA or log-rank test. ns not significant, CON control group, Tuc tucidinostat, aPD-L1 anti-programmed cell death ligand 1 antibody